证券代码：002393 证券简称：力生制药 公告编号：2025-051 天津力生制药股份有限公司 关于调整2022年限制性股票激励计划 回购价格暨回购注销部分激励对象已获授 但尚未解除限售的限制性股票的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 年限制性股票激励计划（草案）及其摘要的议案》以及《关于公司2022年限制性股票激励计 划实施考核管理办法的议案》，公司监事会对本激励计划的相关事项进行了核实并出具了相 关核查意见。 在公司内部进行了公示。公示期内，没有任何组织或个人对激励对象名单提出任何异议。 公司2022年限制性股票激励计划授予激励对象名单的公示情况说明及核查意见》（公告编号： 年限制性股票激励计划（草案）及其摘要的提案》《关于公司2022年限制性股票激励计划实 施考核管理办法的提案》以及《关于提请公司股东大会授权董事会办理2022年限制性股票激 励计划相关事宜的提案》。 制性股票激励计划内幕信息知情人及激励对象买卖公司股票情况自查报告》（公告编号： 审议通过了《关于向激励对象首次授予限制性股票的议案》。确定2022年12月9日为本激励 计 ...

证券代码：002393 证券简称：力生制药 公告编号：2025-057 公司本次回购注销部分激励对象已获授但尚未解除限售的限制性股票的原因、数量、 回购价格及资金来源合法有效，符合《公司法》《管理办法》等法律法规及《公司章程》 《2022 年激励计划》等规定，并履行了必要决策程序。公司本次回购注销部分激励对象 已获授但尚未解除限售的限制性股票程序合法、合规，不存在损害公司及全体股东利益的 情形、不会对公司的财务状况和经营成果产生重大影响。 天津力生制药股份有限公司 监事会关于调整限制性股票激励计划回购价格暨回购注 销部分激励对象已获授但尚未解除限售的限制性股票的 核查意见 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 根据《中华人民共和国公司法》（以下简称"《公司法》"）《中华人民共和国证券 法》《上市公司股权激励管理办法》（以下简称"《管理办法》"）等法律法规及公司《天 津力生制药股份有限公司公司章程》（以下简称"《公司章程》"）《2022 年限制性股 票激励计划（草案）》（以下简称"《2022 年激励计划》"）《2024 年限制性股票激励 计划（草案）》 ...

已获授但尚未解除限售的限制性股票的公告》（公告编号：2025-052）。 根据上述两议案，公司将按照 8.76 元/股和 10.24 元/股回购 88,140 股限制性股票。 回购完毕后，公司将向中国证券登记结算有限责任公司深圳分公司申请该部分股票的注 销。 关于回购注销部分限制性股票减少注册资本暨通知 债权人的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 天津力生制药股份有限公司（以下简称"公司"或"本公司"）于 2025 年 8 月 20 日召开了第七届董事会第五十二次会议及第七届监事会第四十三次会议，审议通过了《关 于调整 2022 年限制性股票激励计划授予价格暨回购注销部分激励对象已获授但尚未解除 限售的限制性股票的议案》和《关于调整 2024 年限制性股票激励计划授予价格暨回购注 销部分激励对象已获授但尚未解除限售的限制性股票的议案》，根据公司 2022 年第五次 股东大会和 2025 年第一次临时股东大会的授权，公司拟对 2 名因离职及退休不再符合激 励条件的激励对象已获授但尚未解除限售的 88,140 股限制性股票进行回购注销。有关内 容 ...

Group 1 - The company, Lisheng Pharmaceutical, announced the convening of its 52nd meeting of the 7th Board of Directors on August 20, 2025, via communication voting [1] - The meeting reviewed the special report on the storage and actual use of raised funds for the first half of 2025 [1] - For the first half of 2025, Lisheng Pharmaceutical's revenue composition was 100.0% from the pharmaceutical industry [1] Group 2 - As of the report, Lisheng Pharmaceutical has a market capitalization of 6.6 billion yuan [1]

Core Viewpoint - Lisheng Pharmaceutical reported a mixed performance in its semi-annual earnings, with a decline in revenue but a significant increase in net profit and earnings per share [2] Financial Performance - The company's revenue for the first half of 2025 was approximately 732 million yuan, representing a year-on-year decrease of 1.76% [2] - The net profit attributable to shareholders was around 343 million yuan, showing a substantial year-on-year increase of 235.04% [2] - Basic earnings per share reached 1.33 yuan, which is an increase of 232.5% compared to the previous year [2]

Core Viewpoint - Lisheng Pharmaceutical reported significant growth in revenue and net profit for the first half of 2025, driven by innovation and strategic investments [2][3]. Financial Performance - The company achieved a revenue of 732 million yuan and a net profit attributable to shareholders of 343 million yuan, marking a year-on-year increase of 235.04% [2]. - The basic earnings per share reached 1.33 yuan, up 232.50% from 0.40 yuan in the same period last year [2]. Strategic Initiatives - Lisheng Pharmaceutical plans to establish a 1 billion yuan equity investment fund in collaboration with Jianxin Equity to enhance business structure and operational strength [2]. - The company has identified over 300 quality merger and acquisition projects as part of its "14th Five-Year" strategic planning [3]. Research and Development - The company invested 60.51 million yuan in R&D, with an investment rate exceeding 8%, resulting in multiple breakthroughs [3]. - Lisheng Pharmaceutical applied for 9 patents and received approval for 3 core products during the first half of the year [3]. Marketing and Production - The company implemented a "four-wheel" marketing system, focusing on the core product Indapamide, which improved sales through a refined distribution network [4]. - Lisheng Pharmaceutical achieved a 100% compliance rate in drug market inspections and completed safety hazard rectifications [4]. Subsidiary Performance - Central Pharmaceutical integrated its marketing team, leading to a 14% increase in sales of Urokinase injection and significant growth in Heparin Sodium injection sales [5]. - The subsidiary San Yu Pharmacy ranked among the top retail pharmacies in Tianjin based on daily sales [5]. Governance and Efficiency - The company established a dynamic monitoring mechanism for loss-making enterprises and improved its ESG management system, achieving a six-year high in market value [6]. - Lisheng Pharmaceutical plans to increase R&D investments and expand its distribution network in the second half of the year [6].

看公告，小e抢先报！ 8月21日晚间上市公司公告精选： 【经营数据】 数码视讯：上半年净利润1670.03万元，同比增2747.64%。 千方科技：上半年净利润1.7亿元，同比增长1287.12%。 苏州固锝：上半年净利润4370.21万元，同比增长310.28%。 蓝特光学：上半年净利润1.03亿元，同比增长110.27%。 中国石化：上半年净利润同比下降39.8%，拟派发半年度现金股息每股0.088元。 快手第二季度总营收350亿元，经调整净利润达56亿元。 三一重工：上半年净利润同比增长46%，拟每10股派3.1元。 【再融资】 山东路桥：公开发行不超40亿元公司债券获证监会注册批复。 赛诺医疗：上半年净利润1384.16万元，同比增长296.54%。 力生制药：上半年净利润3.43亿元，同比增长235.04%。 达意隆：上半年净利润9086.75万元，同比增长217.89%。 国电南自：上半年净利润1.59亿元，同比增长197.03%。 锐捷网络：上半年净利润4.52亿元，同比增194%。 中银证券：江西铜业拟减持公司不超3%股份。 【其他】 莱茵生物：公司发生安全事故。 飞鹿股份：筹划公司控制权变更 ...

Buyback and Shareholder Actions - Sinopec plans to repurchase A-shares with a total fund of no less than RMB 5 billion and no more than RMB 10 billion, potentially reducing its registered capital [1] - Hengbang Mining intends to reduce its stake in the Hong Kong-listed company, WanGuo Gold, by up to 40 million shares, representing approximately 3.69% of WanGuo's total share capital [5] Product Approvals and Market Launches - Wantai Biological's nine-valent HPV vaccine has received the batch release certificate, marking its official market launch and enhancing the company's product lineup [1] - Changchun High-tech's subsidiary has received acceptance for the clinical trial application of GenSci143, a dual-specific antibody drug, which may provide new treatment options for certain tumors [7] Financial Performance - Hongxin Electronics reported a 15.01% increase in revenue to RMB 3.494 billion and a 9.85% rise in net profit to RMB 53.99 million for the first half of 2025 [2] - Sanwei Xinan experienced a net loss of RMB 29.39 million in the first half of 2025, despite a 15.19% increase in revenue to RMB 195 million [3] Corporate Developments - TianTan Bio received a commitment from its controlling shareholder to resolve new competition issues arising from a recent acquisition [4] - Feilu Co. announced a potential change in control, leading to a temporary suspension of its stock trading [8] Investment and Expansion - Jinbei Electric's subsidiary has signed a purchase agreement for a factory in Europe, marking significant progress in establishing its European production base [1] - Shengshi Technology plans to establish a wholly-owned subsidiary to integrate AI and humanoid robot technology with innovative toy products, investing RMB 10 million [6]

（文章来源：证券日报） 证券日报网讯 8月21日晚间，力生制药发布公告称，公司第七届监事会第四十三次会议审议通过了《关 于2025年半年度报告全文及摘要的议案》等多项议案。 ...

智通财经APP讯，力生制药(002393.SZ)发布2025年半年度报告，该公司营业收入为7.32亿元，同比减少 1.76%。归属于上市公司股东的净利润为3.43亿元，同比增长235.04%。归属于上市公司股东的扣除非经 常性损益的净利润为1.04亿元，同比增长5.09%。基本每股收益为1.33元。 ...